K981457

MAY 27 1998

# 510(k) Summary

**Submitter's Name/Address**
Abbott Laboratories
1920 Hurd Drive
Irving, Texas 75038

**Contact Person**
Mark Littlefield
Section Manager MS 1-8
Regulatory Affairs
(972) 518-7861
Fax (972) 753-3367

**Date of Preparation of this Summary:** April 22, 1998

**Device Trade or Proprietary Name:** AlbP

**Device Common/Usual Name or Classification Name:** Albumin BCP

**Classification Number/Class:** 75CJW /Class II

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: _____.

**Test Description:**

Albumin BCP is an *in vitro* diagnostic assay for the quantitative determination of albumin in human serum. The Albumin BCP assay is a clinical chemistry assay in which the albumin in the sample binds to bromcresol purple. The absorbance of the complex is measured at 600 nm and is directly proportional to the albumin concentration in the sample.

**Substantial Equivalence:**

The Albumin BCP assay is substantially equivalent to the Boehringer Mannheim® Albumin BCP Assay (K844426) on the Hitachi® 717 Analyzer.

Both assays yield similar Performance Characteristics.

Similarities to Boehringer Mannheim:

- Both assays are *in vitro* clinical chemistry methods.
- Both assays can be used for the quantitative determination of albumin.
- Both assays yield similar clinical results.

Differences to Boehringer Mannheim:

- There is a minor difference in the assay range.

**Intended Use:**

The Albumin BCP assay is used for the quantitation of albumin in human serum.

**Performance Characteristics:**

Comparative performance studies were conducted using the ALCYON™ Analyzer. The Albumin BCP assay method comparison yielded acceptable correlation with the Boehringer Mannheim Albumin BCP assay on the Hitachi 717 Analyzer. The correlation coefficient = 0.9855, slope = 0.950, and Y-intercept = 0.198 g/dL. Precision studies were conducted using the Albumin BCP assay. Within-run, between-run, and between-day studies were performed using two levels of control material. The total %CV for Level 1/Panel 111 is 2.3% and Level 2/Panel 112 is 2.5%. The Albumin BCP assay is linear up to 7.0 g/dL. The limit of quantititation (sensitivity) of the Albumin BCP assay is 0.1 g/dL. These data demonstrate that the performance of the Albumin BCP assay is substantially equivalent to the performance of the Boehringer Mannheim Albumin BCP assay on the Hitachi 717 Analyzer.

**Conclusion:**

The Albumin BCP assay is substantially equivalent to the Boehringer Mannheim Albumin BCP assay on the Hitachi 717 Analyzer as demonstrated by results obtained in the studies.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

MAY 27 1998

Mark Littlefield
Section Manager, Regulatory Affairs
Abbott Laboratories
1920 Hurd Drive
Irving, Texas 75038

Re: K981457
AlbP
Regulatory Class: II
Product Code: CJW
Dated: April 22, 1998
Received: April 23, 1998

Dear Mr. Littlefield:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Steven Gutman

Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): _____

Device Name: Albumin BCP

Indications For Use:

The Albumin BCP assay is used for the quantitation of albumin in human serum. Albumin BCP measurements are used in the diagnosis and treatment of kidney disease and liver disease.

(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number k981457

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use ✓ OR Over-The-Counter Use_____
(Per 21 CFR 801.109)

(Optional Format 1-2-96)